Daniel Haldar(@DanielHaldarMD) 's Twitter Profile Photo

Pleasure to share our Johns Hopkins Kimmel Cancer Center results from an interception trial studying an off-the-shelf mutant KRAS vaccine in pts at high risk of developing PDAC at

Pleasure to share our @hopkinskimmel results from an interception trial studying an off-the-shelf mutant KRAS vaccine in pts at high risk of developing PDAC at #AACR24 #pancsm
account_circle
Michael Yan, MD MPH(@MichaelYanMD) 's Twitter Profile Photo

First randomized evidence supporting PFS benefit of MDT for OM-pancreatic cancer in P2-EXTEND trial. OS no different, but do other endpoints matter (e.g. maintenance of earlier line systemic therapy)?

First randomized evidence supporting PFS benefit of MDT for OM-pancreatic cancer in P2-EXTEND trial. OS no different, but do other endpoints matter (e.g. maintenance of earlier line systemic therapy)? #GI24 #pancsm
account_circle
MSK Department of Medicine(@MSK_DeptOfMed) 's Twitter Profile Photo

At , our very own Wungki Park, MD, Wungki Park, MD MS of MSKCC Center for Pancreatic Cancer Research is presenting data on molecular profiles and single cell analysis that identified immunogenic pancreatic ductal adenocarcinoma. Check out his poster on Wednesday from 9:00-12:30 in Section 25.

account_circle
Terry Williams(@TeWilliamsMD) 's Twitter Profile Photo

Congrats to Adam Wolfe, MD, PhD, Tiantian Cui MD, PhD, and the rest of the stellar team for the Science Advances publication on nutrient scavenging in . 👏
The work uncovers a pivotal role for caveolae-mediated endocytosis (CME) in fueling growth.

Congrats to @AdamWolfeMDPhD, @cui_tiantian, and the rest of the stellar team for the @ScienceAdvances publication on nutrient scavenging in #pancreaticcancer. 👏
The work uncovers a pivotal role for caveolae-mediated endocytosis (CME) in fueling #PDAC growth.   #pancsm #gism
account_circle
Mike Thompson, MD, PhD, FASCO(@mtmdphd) 's Twitter Profile Photo

Frequency of Common and Uncommon BRAF Alterations among Colorectal and Non-Colorectal Gastrointestinal Malignancies [May 10, 2024] Dr Amit Mahipal et al. Cancers
mdpi.com/2072-6694/16/1…

Frequency of Common and Uncommon BRAF Alterations among Colorectal and Non-Colorectal Gastrointestinal Malignancies [May 10, 2024] @Amitmahipal79 et al. Cancers
mdpi.com/2072-6694/16/1… #PrecisionMedicine #crcsm #esocsm #hpbcsm #pancsm #sbcsm #stcsm
account_circle
Mark Lewis(@marklewismd) 's Twitter Profile Photo

Fantastic morning at for ⁦PanCAN⁩ with my ⁦IntermountainMedCtr⁩ oncology teammates! We are seeing real progress against the wretched scourge that is pancreatic cancer

Fantastic morning at #PurpleStride for ⁦@PanCAN⁩ with my ⁦@IntermtnMedCtr⁩ oncology teammates! We are seeing real progress against the wretched scourge that is pancreatic cancer #pancsm
account_circle
Oncology Brothers(@OncBrothers) 's Twitter Profile Photo

now FDA Oncology approved for 1L metastatic based off : NALIRIFOX vs. Gem/Abrax

- mOS 11.1mos Vs 9.2mos (HR: 0.83)
- Cross trial comparison, similar OS w/ FOLFIRINIOX
- Save liposomal for later lines?

#LiposomalIrinotecan now @FDAOncology approved for 1L metastatic #PancreaticCancer based off #NAPOLI3: NALIRIFOX vs. Gem/Abrax

- mOS 11.1mos Vs 9.2mos (HR: 0.83)
- Cross trial comparison, similar OS w/ FOLFIRINIOX
- Save liposomal for later lines?

#gism #pancsm #OncTwitter
account_circle
Kathrin Heinrich(@heinrich_kat) 's Twitter Profile Photo

Now live at - Upper GI Poster discussion.

First data of the 3-Arm Arbeitsgemeinschaft Internistische Onkologie - AIO FOOTPATH trial in metastatic presented by Ben Westphalen .

In FOOTPATH, sequential application of NAPOLI/FOLFOX was found to be effective and well tolerated.

OncoAlert 🚨

Now live at #ASCO23 - Upper GI Poster discussion. 

First data of the 3-Arm @AIO_Onkologie FOOTPATH trial in metastatic #pancsm presented by @BenWestphalen .

In FOOTPATH, sequential application of NAPOLI/FOLFOX was found to be effective and well tolerated.   

@OncoAlert 🚨
account_circle
Kathrin Heinrich(@heinrich_kat) 's Twitter Profile Photo

Our case of a patient with with MSI & BRAF fusion is now out in JCO Precision Oncology

ascopubs.org/doi/10.1200/PO…

👉BRAF fusion as an alternative route to MSI
👉excellent & long lasting response to

OncoAlert 🚨 Ben Westphalen 💜

Our case of a patient with #pancreaticcancer with MSI & BRAF fusion is now out in @JCOPO_ASCO 

ascopubs.org/doi/10.1200/PO… 

👉BRAF fusion as an alternative route to MSI
👉excellent & long lasting response to #immunotherapy

@OncoAlert 🚨 @BenWestphalen #PancSM 💜 #PrecisionMedicine
account_circle
Mark Lewis(@marklewismd) 's Twitter Profile Photo

Superb graphic 👇 from a JAMA review on pancreatic cancer visualizing the peripancreatic vessels vis a vis operable vs. borderline resectable vs. locally advanced

As a non-surgeon I will be saving this for my discussions with patients

pubmed.ncbi.nlm.nih.gov/34547082/

Superb graphic 👇 from a @JAMA_current review on pancreatic cancer visualizing the peripancreatic vessels vis a vis operable vs. borderline resectable vs. locally advanced

As a non-surgeon I will be saving this for my discussions with patients  #pancsm 

pubmed.ncbi.nlm.nih.gov/34547082/
account_circle
Emil Lou, MD, PhD, FACP(@cancerassassin1) 's Twitter Profile Photo

Congratulations to Erik Faber, MD, PhD, former University of Minnesota MD-PhD Program, current The Osler Medical Residency, future GI Oncologist, et al for this tour de force new pub breaking down pancreatic carcinoma TME & IO markers by KRAS expression. Another one from Caris Life Sciences POA GI Group

sciencedirect.com/science/articl…

Congratulations to @fabermdphd, former @UMNMSTP, current @OslerResidency, future GI Oncologist, et al for this tour de force new pub breaking down pancreatic carcinoma TME & IO markers by KRAS expression. Another one from @carisls POA GI Group

sciencedirect.com/science/articl… #pancsm
account_circle
Jasminka Criley MD, FACP, FHM(@criley_md) 's Twitter Profile Photo

It has been a tough road.
This rainbow brought her luck,
as surgeons were doing their magic.
It bought her some more time.
Some.
Not too much.

How much time before leaving this world is too much?
Never.

It has been a tough road. 
This rainbow brought her luck,
as surgeons were doing their magic.
It bought her some more time.
Some. 
Not too much. 

How much time before leaving this world is too much?
Never.

#pancreaticcancer #pancsm #oncology #onctwitter #medtwitter #crileymd
account_circle
The Lancet Gastroenterology & Hepatology(@LancetGastroHep) 's Twitter Profile Photo

New research - Timmer et al - MRI-guided stereotactic ablative body radiotherapy versus CT-guided percutaneous irreversible electroporation for locally advanced pancreatic cancer: the CROSSFIRE phase 2 trial

thelancet.com/journals/langa…

New research - Timmer et al - MRI-guided stereotactic ablative body radiotherapy versus CT-guided percutaneous irreversible electroporation for locally advanced pancreatic cancer: the CROSSFIRE  phase 2 trial 

thelancet.com/journals/langa… 

#GITwittter #OncTwitter #PanCSM
account_circle
Memorial Sloan Kettering Radiation Oncology(@MSK_RadOnc) 's Twitter Profile Photo

The Amer. Radium Society multiD GI expert panel developed these Appropriate Use Criteria evaluating the evidence regarding neoadjuvant tx for pts with , including surgery, systemic tx, & radiotherapy for both oncologic outcomes & QOL.
journals.lww.com/amjclinicalonc…

The @RadiumSociety multiD GI expert panel developed these Appropriate Use Criteria evaluating the evidence regarding neoadjuvant tx for pts with #pancreaticCancer, including surgery, systemic tx, & radiotherapy for both oncologic outcomes & QOL. #pancsm
journals.lww.com/amjclinicalonc…
account_circle